HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
Informed and written signed consent
Participant with regular health insurance
Participant under guardianship or curatorship
Participant with free State medical assistance
Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.
ANRS, Emerging Infectious Diseases
Lead sponsor
INSERM SC10-US19
Collaborator